INTRODUCTION
Streptomycetes are Gram-positive filamentous soil bacteria with a complex life cycle that involves morphological differentiation such as sporulation. They are also widely known for their ability to produce a variety of commercially valuable enzymes and secondary metabolites, including antibiotics, anti-tumour agents, immunosuppressants and enzyme inhibitors (Chater, 1989; Hopwood, 1988; Strauch et al., 1991; Myles, 2003; Hranueli et al., 2005) . It has been well documented that secondary metabolite production generally occurs at the onset of the stationary phase of growth of Streptomyces spp. and correlates temporally with the formation of aerial mycelium in cultures grown on the surface of solid media (Chater & Bibb, 1997; Martin et al., 2000; Bibb, 2005) . Previous studies have revealed that the regulation of secondary metabolite production in Streptomyces spp. involves a complex regulatory network in response to nutritional and environmental factors, operating at several layers of control. Some of these affect only antibiotic production, whereas others affect both antibiotic production and morphological differentiation, suggesting that the two processes share some elements of genetic control (Chater & Bibb, 1997) , while others are unique.
Among this regulatory network, the genes working at the proximal level usually reside within the respective biosynthetic gene cluster and are pathway-specific regulatory genes that only affect a single secondary metabolite biosynthetic pathway. The best-characterized pathwayspecific regulatory proteins, including ActII-ORF4 for actinorhodin biosynthesis from Streptomyces coelicolor A3(2) (Arias et al., 1999; Wietzorrek & Bibb, 1997) and DnrI for doxorubicin biosynthesis from Streptomyces peucetius (Sheldon et al., 2002) , belong to the so-called Streptomyces antibiotic regulatory proteins (SARPs) family (Wietzorrek & Bibb, 1997) . These regulatory proteins contain a unique OmpR-like DNA-binding domain that is quite different from the typical domain with a helix-turnhelix (HTH) motif (Sheldon et al., 2002; Wietzorrek & Bibb, 1997) . Unlike the SARP family (typically between 277 and 665 aa), another important, less-studied transcriptional family of regulators has recently been found in several macrolide antibiotic pathways (De Schrijver & De Mot, 1999) , which are relatively large in size (872 to 1 159 aa) and have an N-terminal ATP-binding domain represented by discernible Walker A and B motifs (Walker et al., 1982) and a C-terminal LuxR-type DNA-binding domain (Henikoff et al., 1990) . Regulators belonging to this socalled LAL (large ATP-binding regulators of the LuxR) family, whose prototype member is the Escherichia coli MalT, involved in the uptake and catabolism of maltodextrins (Richet & Raibaud, 1989) , have been identified and characterized in several macrolide antibiotic pathways, including PikD for pikromycin from Streptomyces venezuelae (Wilson et al., 2001) , RapH for rapamycin from Streptomyces hygroscopicus (Aparicio et al., 1996; Molnár et al., 1996) and NysRI/RIII for nystatin from Streptomyces nouresi (Brautaset et al., 2000) .
Tautomycetin (TMC), a secondary metabolite produced by Streptomyces sp. CK4412, is a novel activated T-cell-specific immunosuppressive compound with an ester bond linkage between a terminal cyclic anhydride moiety and a linear polyketide chain bearing an unusual terminal alkene, whose chemical structure is identical to a previously reported antifungal compound produced by Streptomyces griseochromogenes (Cheng et al., 1989) . Inhibition of T cell proliferation by TMC was observed at concentrations 100-fold lower than those needed to achieve maximal inhibition with cyclosporin A (CsA) (Shim et al., 2002) . Due to its promising characteristics, TMC, whose mechanism of action is different from CsA or FK506, has been identified as a new drug candidate with potent T-cell-specific immunosuppressive activity (Shim et al., 2002) . Previously, we isolated and characterized the entire TMC biosynthetic gene cluster from Streptomyces sp. CK4412 originating from Jeju Island, Korea, and demonstrated its identity by gene disruption analysis (Choi et al., 2007) . The TMC biosynthetic gene cluster revealed two ORFs encoding a typical modular polyketide synthetase (PKS) gene as well as 12 ORFs located at both flanking regions, the deduced functions of which were consistent with TMC biosynthesis (Fig. 1) .
Here, we describe the cloning and characterization of tmcN, a TMC pathway-specific regulatory gene located at the downstream end of the TMC biosynthetic gene cluster. We also demonstrate its role as a LAL-family pathwayspecific transcriptional activator for TMC biosynthesis via tmcN gene disruption-complementation as well as RT-PCR-driven TMC gene expression analysis in Streptomyces sp. CK4412.
METHODS
Bacterial strains and culture conditions. Streptomyces sp. CK4412, kindly provided by ForHumanTech Ltd, Korea, was used as a TMCproducing strain as well as the source of DNA for tmcN gene disruption and its complementation (Table 1) (Shim et al., 2002) . The strain was cultivated at 28 uC in either R2YE or YEME liquid medium (Kieser et al., 2000) . E. coli DH5a was used for DNA cloning and plasmid propagation. E. coli XL-1 Blue MR was used for cosmid library construction. E. coli ET12567/pUZ8002 (dam2 dcm2 hrdM) was used as the transient host for E. coli-Streptomyces conjugation (Choi et al., 2004) . All E. coli strains were cultured at 37 uC in Luria broth or on Luria agar, supplemented with the appropriate antibiotics when needed (Kieser et al., 2000) .
Cloning and sequence analysis of tmcN. The tmcN gene was identified in a previously isolated pTMC2290 cosmid (GenBank accession number, DQ983361) after the complete sequencing of the three positive cosmid clones, performed at Genotech, Korea (Table 1 ) (Choi et al., 2007) . DNA sequences for tmcN were assembled using BLAST searches on the National Center for Biotechnology Information (NCBI) server, and the ORF was subsequently predicted using the web-based program FramePlot 2.3.2 (http://www.nih.go.jp/~jun/cgibin/frameplot.pl).
Construction of a tmcN mutant via chromosomal gene disruption. The tmcN gene encoding a putative LuxR family regulator with an ATP-binding site located downstream of the PKS tmcB gene was inactivated using a PCR-targeted gene-disruption system (Gust et al., 2003) . An apramycin-resistance gene/oriT cassette for the replacement of tmcN was amplified using the pIJ773 as a template (Gust et al., 2003) using the following primers: forward primer (59-tcagatccgtctcgcttcg tgtgctcgtcaccgtgccgttATTCCGGGG-ATCCGTCGACC-39) and reverse primer (59-acgaatatcgccggcatctgaccacgttcgaggtcacggtTGTAGGCTGGAGCTGCTTC-39). The lowercase type represents 40 nt homologous extensions to the DNA regions inside tmcN. This cassette was introduced into E. coli BW25113/ pIJ790 containing pTMC2290. Gene replacement in tmcN was confirmed by restriction analysis of the mutated pTMC2290 Tautomycetin biosynthetic pathway-specific regulator (pTMC2290DtmcN). pTMC2290DtmcN was introduced into Streptomyces sp. CK4412 by conjugation from E. coli ET12567/ pUZ8002. After incubation at 28 uC for 16 h, each plate was overlaid with 1 ml sterile water containing apramycin at a final concentration of 50 mg ml 21 and nalidixic acid at a final concentration of 25 mg ml
21
. Incubation was continued at 28 uC until conjugants appeared. The double-crossover exconjugants were selected using a standard Apr R /Kan S method (Gust et al., 2003) , followed by the confirmation of both Streptomyces sp. CK4412 and Streptomyces sp. CK4412-002 (DtmcN mutant of Streptomyces sp. CK4412) genomic DNAs by both PCR and Southern blot hybridization. Three different PCR primers for the confirmation of the double-crossover recombinants were tmcN test primer F (5-AAGCTTAGTCGTCGTGGGTCGCCGGGCT-GGACA-3), tmcN test R (59-AAAGCGTCATCCTGCTCAA-3) and oriT test primer F (59-GAATTCAGCGTGACATCATTCTGTGG-39), which is in the apr R /oriT cassette. (Fig. 3a) .
Construction of integrative plasmid for tmcN complementation. For complementation of the tmcN-disrupted mutant, a 3 kb DNA fragment including the entire tmcN gene was amplified by PCR using genomic DNA from the wild-type (wt) TMC-producing strain (Streptomyces sp. CK4412) as a template and the primer pair PtmcNforward (59-TCTGGAATTCCGAGGGTGAGCTCTTCACGACCATT-39) and PtmcN-reverse (59-AAGCTTAGTCGTCGTGGGTCGCC-GGGCTGGACA-39). The underlined sequences indicate EcoRI and HindIII restriction sites, respectively. PCR was performed in a final volume of 20 ml containing 0.4 mM each primer, 0.25 mM of each of the four dNTPs (Roche), 1 ml extracted DNA, 1 U Ex Taq polymerase with its recommended reaction buffer (TaKaRa) and 10 % DMSO. Subsequent amplifications were then performed in a Rapid Cycler (Idaho Technology) according to the following profile: 30 cycles of 30 s at 95 uC, 30 s at 48 uC and 40 s at 68 uC. The amplified PCR product was analysed by electrophoresis in 1 % (w/v) agarose gel, purified via a DNA extraction kit (Qiagen) and then ligated into pMD18-T (TaKaRa); the sequence was confirmed by complete nucleotide sequencing (Genotech Korea). The PCR-amplified tmcN gene was cloned into EcoRI-digested pSET152 (apr R , pUC18 replicon, WC31, attP); the neomycin-resistance gene originating from pFDNEO-S plasmid (Denis & Brzezinski, 1991) was cloned into the EcoRV restriction site in pSET152 (Bierman et al., 1992) . Finally, neomycin was used for selection of the recombinant Streptomyces sp. CK4412-002/tmcN 2 strain, which was already resistant to apramycin due to tmcN gene disruption.
Isolation of total RNA and gene expression analysis by RT-PCR. Streptomyces sp. CK4412 and Streptomyces sp. CK4412-002 were grown for 72 h in R2YE medium, and the cultures were washed twice with 1 vol. sterile water. The mycelia were subsequently harvested by centrifugation and immediately frozen by immersion in liquid nitrogen. The frozen mycelia were then broken by shearing in a mortar, and the frozen lysate was added to buffer RLT (Qiagen) in the presence of 1 % b-mercaptoethanol. RNeasy mini spin columns were used for RNA isolation according to the manufacturer's instructions. RNA preparations were treated with DNase I (Qiagen) to eliminate possible chromosomal DNA contamination.
DNase I-treated RNA (7 mg) was used as a template for reverse transcription at 50 uC with an AVM Reverse Transcriptase XL (TaKaRa) and random hexamers. The conditions for cDNA synthesis were as follows: 30 uC for 10 min, 50 uC for 1 h, 99 uC for 2 min, 5 uC for 5 min. The resulting cDNA was used for PCR amplification under the following conditions: 25 cycles of denaturation at 95 uC for 30 s, annealing at 60 uC for 30 s and extension at 68 uC for 35 s. Each primer pair of TMC biosynthetic genes was carefully designed to generate a PCR product of approximately 150 to 200 bp using a genscript site (http://www.genscript.com/ssl-bin/app/primer). The complete RT-PCR primer pair sequences are listed in Supplementary Table S1 ; the RNA samples that had not been subjected to RT reaction were used for PCR as negative controls.
HPLC quantification and antifungal bioassay for TMC. For HPLC analysis, culture broth supernatants were extracted with equal volumes of chloroform. The extracts were dried using a rotoevaporator and then resuspended in methanol. Extracts were fractionated by HPLC using isocratic conditions of methanol/water/buffer (1 % diethylamine/formic acid, pH 7.3) 75 : 15 : 10 on a Genesis C18 4 mm column and with UV detection at 273 nm. TMC production was also evaluated by a biological assay against Aspergillus niger, using a paper disc containing the same culture broth extract as used in the HPLC assay. The paper disc was placed on top of A. niger that had been incubated on ME medium (0.05 % malt extract, 0.05 % glucose, 0.001 % peptone in 1 l double-distilled H 2 O) for 6 h at 30 uC, followed by measurement of the inhibition zone after overnight incubation at 30 uC.
RESULTS AND DISCUSSION
In silico sequence analysis of tmcN Previously, we reported that a 3 kb ORF (tmcN) located downstream of tmcB resembled a pathway-specific regulatory gene due to its chromosomal location within tmc, as well as its homology to LuxR-family regulatory genes (Choi et al., 2007) , often found in secondary metabolite gene clusters of Gram-positive bacteria (Haydock et al., 2005) . Further characterization of the tmcN gene product via database- Notably, the predicted amino acid sequence of TmcN shows two highly conserved domains: a putative HTH motif in the C-terminal region typically found in various bacterial DNAbinding proteins (Pabo & Sauer, 1992) and Walker A and B nucleoside triphosphate binding motifs at the N-terminal region (Walker et al., 1982 ; Fig. 2 ). The latter have also been found in polyketide biosynthetic regulatory proteins, including PikD for pikromycin from S. venezuelae (Wilson et al., 2001) , RapH for rapamycin from S. hygroscopicus (Aparicio et al., 1996; Molnár et al., 1996) and NysRI/RIII for nystatin from S. nouresi (Brautaset et al., 2000) . Since all these proteins were previously assigned to the LAL-family (Demain & Fang, 1995) . This may be a further indication of a regulatory role of TmcN in TMC biosynthesis, since most of the known TTA-containing genes specify regulatory or resistance proteins associated with antibiotic biosynthesis gene clusters (Leskiw et al., 1991; Li et al., 2007) .
Construction of a tmcN disruption mutant, Streptomyces sp. CK4412-002
Although the organization and in silico sequence analysis of tmcN in the TMC cluster from Streptomyces sp. CK4412 is consistent with a regulatory role in TMC biosynthesis, we sought to confirm the in vivo function of tmcN using a gene disruption approach. Inactivation of tmcN was performed using a PCR-targeted gene disruption system (see Methods). pTMC2290 was replaced by an apramycinresistance/oriT cassette, generating pTMC2290DtmcN, which was introduced into Streptomyces sp. CK4412 by conjugative gene transfer (Fig. 3a) . Construction of the tmcN mutant (named Streptomyces sp. CK4412-002) generated by PCR-targeted disruption was confirmed by both PCR and Southern hybridization analysis. The Tautomycetin biosynthetic pathway-specific regulator expected 1.43 kb PCR-amplified band was observed in genomic DNA samples isolated from Streptomyces sp. CK4412, and a band of the expected size (1.53 kb) was observed in genomic DNA samples isolated from Streptomyces sp. CK4412-002 (Fig. 3b) . A PCR-amplified fragment of the expected size (0.47 kb), amplified using an alternative PCR primer pair designed to detect an apramycin resistance gene/oriT cassette, was observed only in the Streptomyces sp. CK4412-002 (Fig. 3b) . Moreover, two different theoretically calculated BamHI digestion patterns were observed in Southern hybridization with Streptomyces sp. CK4412 and Streptomyces sp. CK4412-002 (Fig. 3c) , implying that tmcN was specifically disrupted as expected.
Loss of TMC production by tmcN disruption and rescue by tmcN complementation Fermentation broths of both Streptomyces sp. CK4412 and Streptomyces sp. CK4412-002 grown under conditions optimal for TMC production were extracted with chloroform, followed by an antifungal bioassay and HPLC quantification for the presence of TMC. Although very weak antifungal activity was detected, presumably due to either residual TMC or some other unconfirmed metabolites produced by Streptomyces sp. CK4412, the significantly reduced antifungal activity against A. niger, as well as the absence of TMC in extracts of Streptomyces sp. CK4412-002 under the same culture conditions, provide strong evidence that tmcN plays an essential regulatory role in TMC biosynthesis (Fig. 4) .
To prove further that the inactivation of tmcN was indeed responsible for TMC production, we performed genetic complementation of Streptomyces sp. CK4412-002 by expressing tmcN under the control of its own promoter. For this purpose, we used the integrating conjugative vector pSET152 (Bierman et al., 1992) , into which the coding region of tmcN and 144 bp of the DNA region upstream of the putative translational start point was cloned, resulting in pSETNEOtmcN. Also, a neomycinresistance gene, originated from plasmid pFDNEO-S (Denis & Brzezinski, 1991) , was inserted into the multiple cloning site (MCS) of parental pSET152 to select the recombinant strains bearing complementation plasmids. Both HPLC and the bioassay confirmed that TMC productivity and antifungal activity were restored to significant levels in the Streptomyces sp. CK4412-002 mutant strain carrying pSETNEOtmcN (Fig. 4) , implying that the absence of TMC productivity from Streptomyces sp. CK4412-002 strains was due to a lack of a TMC-specific positive regulatory gene, tmcN. Moreover, the wild-type Streptomyces sp. CK4412 strain containing an extra copy of tmcN via chromosomal integration of pSETNEOtmcN led to an approximately 5.5-fold increase in TMC biosynthesis (Fig. 4a) .
Transcriptional control of TMC biosynthetic pathway genes
Total RNA samples were prepared from the Streptomyces sp. CK4412 wild-type and the Streptomyces sp. CK4412-002 mutant after 72 h of growth and used as a template for gene expression analysis by RT-PCR. Primers for RT-PCR were specific to sequences within tmc genes (Table 2) and were designed to produce cDNAs of approximately 200 bp. A primer pair designed to amplify a cDNA of the rRNA gene was used as an internal control. Transcripts were analysed from the 14 genes located within the tmc cluster, including tmcN, after 25 PCR cycles. This analysis was carried out at least three times for each primer pair. In the RT-PCR analysis, the transcripts of all 14 genes were detected in the Streptomyces sp. CK4412 wt, while the transcription pattern in the Streptomyces sp. CK4412-002 was significantly reduced for most of the tmc genes within the cluster, except for tmcN (Fig. 5) . Interestingly, the transcripts of the putative PKS operon containing the translationally coupled genes tmcA and tmcB were apparently much less affected by the absence of the tmcN gene in the Streptomyces sp. CK4412-002 (Fig. 5) . The absence of the tmcM transcript is believed to be a polar effect derived from tmcN disruption in the Streptomyces sp. CK4412-002 due to translational coupling of these two genes, even though the PCR-targeting method is designed to limit this effect. Real-time RT-PCR analysis also confirmed that the absence of tmcN reduced transcripts of the PKS operon less significantly (only 33 % reduction), while both flanking operons were severely affected by the absence of tmcN (88 % reduction for tmcC operon and 63 % reduction for tmcJ operon, respectively) (see Supplementary Fig. S1 , available with the online version of this paper). These results strongly suggest that TmcN might activate all three putative TMC operons at different levels, either directly or indirectly. Taken together, these data demonstrate that tmcN encodes a LAL-family pathway-specific activator of the TMC biosynthetic pathway in Streptomyces sp. CK4412.
Concluding remarks
Regulation of natural product biosynthesis in Streptomyces spp. continues to represent an understudied aspect of the field. Despite the power of genome sequencing and transcriptomics, understanding the details of regulation of secondary metabolic systems demands genetic and biochemical dissection of specific regulators to elucidate their genetic targets and effects. The LAL family of regulators has been recognized in several systems (Wilson et al., 2001; Aparicio et al., 1996; Molnár et al., 1996; Brautaset et al., 2000) , and the study described in this report has revealed that TmcN exerts its effects at different levels on individual operons in this large biosynthetic gene cluster. Gene disruption and complementation studies have confirmed its role as a positive regulator, and the ability to increase production of this important metabolite by adding an additional copy of tmcN into the chromosome demonstrates the value of this strategy for strain improvement. Currently, one of the key factors for further development of TMC as a medicinal agent is the limited amount of this natural product available through fermentation methods. Thus, this initial study of TmcN paves the way for further analysis of this growing class of regulatory factors and offers a new approach to improving access to TMC for detailed biological studies, target identification and analogue development. 
